Published: June 2010
A Rare Malignant Triton TumorTripathy K.a · Mallik R.b · Mishra A.a · Misra D.c · Rout N.d · Nayak P.b · Samantray S.d · Rath J.a
aDepartment of Pathology, S.C.B. Medical College, Cuttack, bDepartment of Pathology, Kalinga Institute of Medical Science, Bhubanneswar, cDepartment of Pathology, MKCG Medical College, Berhmpur, and dDepartment of Pathology, Acharaya Harihar Regional Cancer Institute, Cuttack, India
Dr. Kalpalata Tripathy, MD (Path)
Department of Pathology, S.C.B. Medical College
Cuttack 753007 (India)
Tel./Fax +91 674 254 1616, E-Mail firstname.lastname@example.org
Do you have an account?
Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation, malignant triton tumor, has a rare incidence. We report such a case in a 40-year-old male who presented with a mass over the buttock. He was a previously diagnosed case of neurofibroma in the same area. Histomorphology supported by immunostaining with S-100 protein confirmed the diagnosis. Malignant triton tumor has a poor prognosis owing to its aggressive biological behavior. The fact that the presence of this tumor in the buttock region is extremely rare has prompted the authors to report this case.
© 2010 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.